Trial Profile
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Ewing's sarcoma; Hodgkin's disease; Malignant melanoma; Neuroblastoma; Neuroectodermal tumours; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 06 Apr 2023 Status changed from active, no longer recruiting to completed.
- 15 Dec 2022 Planned End Date changed from 5 Oct 2022 to 30 Sep 2023.
- 03 Oct 2022 Results (n=52) assessing safety and efficacy from part C, D E of this trial published in the Clinical Cancer Research